Summary by Moomoo AI
Platinum Pharmaceuticals-B (02142) issued a positive profit warning, projecting a profit of about $1800 million in 2023, compared with a loss of about $1.37 million in 2022, a reversal in profits. This transformation is primarily driven by increased business efficiency, improved cost control, and increased revenue from the licensing and collaboration of innovative products such as HBM7008 and HBM9161 in the Harbor Therapeutics portfolio. In addition, strategic partnerships with global pharmaceutical companies, such as the development and commercialization of HBM9033, as well as Nona Biologicals' ongoing global industry and business development, have significantly driven revenue growth. The Board of Directors reminds shareholders and potential investors that the above financial data are preliminary estimates, unaudited, and that the actual performance may differ from the information disclosed in the announcement and should therefore not be used as investment data. The company will publish the annual results of the audit by the end of March 2024.